ASLAN Pharmaceuticals (ASLN) News Today $0.60 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 19, 2024 | msn.comASLAN stock tumbles 54% after board votes to liquidateJuly 19, 2024 | msn.comWhy ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%July 19, 2024 | msn.comWhy ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionJuly 17, 2024 | globenewswire.comASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary LiquidationJuly 15, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to AppealMay 21, 2024 | globenewswire.comASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International ConferenceMay 9, 2024 | globenewswire.comASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL EventMay 2, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other BiologicsApril 30, 2024 | globenewswire.comASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to DupilumabApril 24, 2024 | finance.yahoo.comASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International ConferenceApril 22, 2024 | markets.businessinsider.comAslan Announces Positive Results For Phase 2 Study Of Eblasakimab In AD PatientsApril 22, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis PatientsApril 20, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 19, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq NoticeApril 14, 2024 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateApril 12, 2024 | msn.comASLAN Falls On Q4 FiguresApril 12, 2024 | markets.businessinsider.comASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023April 12, 2024 | globenewswire.comASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comAslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and DisordersMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)March 18, 2024 | finance.yahoo.comASLN Apr 2024 5.000 callMarch 17, 2024 | seekingalpha.comWeek In Review: Under Pressure From U.S. Congress, WuXi AppTec Resigns From BIOMarch 14, 2024 | finance.yahoo.comSmart Home Healthcare Market to Reach USD 160.7 Billion by 2032, at 24.3% CAGR: Astute AnalyticaMarch 14, 2024 | finance.yahoo.comREGN May 2024 885.000 callMarch 12, 2024 | msn.comASLAN Pharmaceuticals announces $5M registered direct offeringMarch 12, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 02:03 PM with a stated reason of "LULD pause."March 12, 2024 | globenewswire.comASLAN Pharmaceuticals Announces $5 Million Registered Direct OfferingMarch 12, 2024 | realmoney.thestreet.comPiper 'confident' partner or buyer will see benefit of Aslan's eblasakimabMarch 11, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12%March 11, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 03:03 PM with a stated reason of "LULD pause." Trading set to resume at 03:03 PM. March 11, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 03:03 PM with a stated reason of "LULD pause."March 11, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 03:03 PM with a stated reason of "LULD pause." Trading set to resume at 03:03 PM. March 11, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 02:03 PM with a stated reason of "LULD pause."March 11, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 02:03 PM with a stated reason of "LULD pause."March 11, 2024 | marketbeat.comTrading was temporarily halted for "ASLN" at 02:03 PM with a stated reason of "LULD pause."March 11, 2024 | msn.comBank Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday TradingMarch 6, 2024 | finance.yahoo.comASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific AdvisorsMarch 4, 2024 | msn.comAsian Equities Traded in US as ADRs Edge Higher Monday AfternoonFebruary 29, 2024 | msn.comTech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday TradingFebruary 29, 2024 | globenewswire.comASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for FarudodstatFebruary 28, 2024 | msn.comBank, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower WednesdayFebruary 27, 2024 | msn.comAsian Equities Traded in the US as American Depositary Receipts Rise in Tuesday TradingFebruary 20, 2024 | finance.yahoo.comASLAN Pharmaceuticals Limited (ASLN)February 20, 2024 | morningstar.comASLAN Pharmaceuticals Ltd ADRFebruary 17, 2024 | wsj.comAslan Pharmaceuticals Ltd. ADRDecember 14, 2023 | msn.comTechnology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday TradingDecember 12, 2023 | finanznachrichten.deASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat ProgramsDecember 12, 2023 | finance.yahoo.comASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat ProgramsDecember 4, 2023 | msn.comAsian Equities Traded in the US as American Depositary Receipts Open Week Sharply Lower in Monday Trading Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Email Address We just added a $300 account credit to your MarketBeat subscription (Ad)MarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days. Start Your Risk-Free Trial Here ASLN Media Mentions By Week ASLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASLN News Sentiment▼0.650.62▲Average Medical News Sentiment ASLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASLN Articles This Week▼41▲ASLN Articles Average Week Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KA News ADXN News ABVC News NCNA News CYCN News SBFM News PULM News SNOA News SHPH News GRTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASLN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
